David Rawlings
, Program Director · University of Washington School of Medicine
Credentials: · ·
History
- Present
Center for Immunity and Immunotherapies · University of Washington School of Medicine
- Present
Program for Cell and Gene Therapy · University of Washington School of Medicine
Pediatric Rheumatology
Research
Immunity · 2010 · 1,303 citations
Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia
Cell · 1993 · 1,142 citations
Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice
Science · 1993 · First of over 10 authors · 770 citations
- AS
28 papers
27 papers
22 papers
22 papers
- TT
20 papers
- RK
17 papers · 3 as a resident
15 papers · 3 as a fellow
12 papers
Grants
- 1975–2026
Research Training in Rheumatology
National Institute of Arthritis and Musculoskeletal and Skin Diseases · T32
PI · $3.1M · University of Washington
- 2022–2026
Harnessing Engineered T Regulatory Cells to Promote Beta Cell Health in T1D
National Institute of Diabetes and Digestive and Kidney Diseases · R01
PI · $3.9M · Benaroya Research Inst at Virginia Mason
- 1997–2024
Lentiviral Gene Therapy for Sickle Cell Disease And Immunodeficiency Disorders
National Heart, Lung, and Blood Institute · P01
Project lead · $3.1M · St. Jude Children's Research Hospital
- 2022
Cell and Gene Therapy for Nonmalignant Blood Disorders
National Heart, Lung, and Blood Institute · P01
Project lead · $768.6K · Fred Hutchinson Cancer Center
Clinical trials
- 2014–2019
Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990
Study chair · Completed
National Institute of Allergy and Infectious Diseases (NIAID)